Metronidazole is administered as a prodrug, meaning it enters pathogen cells in an inert form and must be chemically reduced inside the cell before it can inflict damage. This requirement for intracellular activation is not a design flaw but the secret of the drug’s exquisite selectivity. Anaerobic and microaerophilic organisms, which include the amoeba Entamoeba histolytica, the intestinal flagellate Giardia lamblia, the sexually transmitted parasite Trichomonas vaginalis, and the stomach-dwelling bacterium Helicobacter pylori, rely on low-redox-potential fermentation pathways that oxygen-dependent human cells lack. These pathways unwittingly serve as activation machinery, reducing the nitro group of metronidazole to generate short-lived nitro radical anions. Once formed, these radicals transfer electrons to oxygen or to cellular macromolecules, ultimately producing DNA strand breaks, protein damage, and other lesions that trigger catastrophic cell death. The drug, in effect, hijacks the very biochemistry that lets these pathogens survive without oxygen.

The review delineates four major activation pathways, along with an additional route that appears to operate only in Trichomonas. The classical and best-characterized route runs through pyruvate-ferredoxin oxidoreductase, or PFOR, an enzyme central to anaerobic energy metabolism. PFOR passes electrons to low-molecular-weight electron carriers such as ferredoxin, and metronidazole acts as an electron acceptor downstream of these carriers, receiving the electrons that convert it into its cytotoxic radical form. This arrangement explains why disruptions to PFOR expression or to ferredoxin-mediated electron transport so frequently accompany resistance in Entamoeba, Giardia, and Trichomonas. When the electron pipeline that feeds the drug’s activation is throttled back, less of the prodrug is converted into its lethal form, and the parasite gains a survival advantage.

Beyond the classical pathway, the review highlights a family of enzymes known as oxygen-insensitive nitroreductases, or NTRs, which can activate metronidazole independently of the ferredoxin-linked machinery. These nitroreductases reduce the nitro group through a two-electron mechanism that does not require the extremely low oxygen tensions that inhibit other reductive routes. Their existence demonstrates that pathogen cells possess redundant means of arming the drug, a feature that complicates resistance strategies because a parasite must suppress every activation pathway to fully protect itself. Indeed, the review emphasizes that resistant isolates often show layered changes, combining reduced PFOR activity with altered nitroreductase expression and shifts in overall redox metabolism.

Counterbalancing the activators are enzymes that perform the opposite function. Nitroimidazole reductases, known as NIMs, reduce metronidazole in a manner that avoids the formation of the toxic nitro radical, instead converting the compound into non-cytotoxic derivatives. In Entamoeba, the presence or upregulation of such detoxifying activity can dramatically blunt the drug’s effectiveness, contributing directly to resistance phenotypes. The balance between activation enzymes and detoxification enzymes therefore functions as a molecular seesaw: the tipping point determines whether a given dose of metronidazole sterilizes the infection or merely selects for a hardier parasite population. Understanding the genetic and environmental factors that tilt this balance is now a central goal for researchers seeking reliable biomarkers of treatment failure.

Perhaps the most striking recent advance documented in the review is the identification of an alternative activation route involving the malic enzyme. This metabolic enzyme, long appreciated for its role in decarboxylating malate and shuttling reducing equivalents within parasite cells, appears capable of reducing metronidazole and thereby contributing to its activation. The discovery expands the roster of host enzymes that the drug can co-opt and suggests that resistance mechanisms targeting only the classical PFOR-ferredoxin axis may leave this secondary route intact. It also raises intriguing questions about how metabolic flux within the parasite cell, shaped by nutrient availability and environmental conditions, might modulate drug efficacy from one infection context to another.

Equally consequential is the emerging understanding of how activated metronidazole actually kills the parasite. Rather than a nonspecific barrage of radical damage, cell death in Entamoeba histolytica appears to unfold through an organized program. The review’s authors report that metronidazole-associated oxidative stress induces the activation of apoptosis-inducing factor, a mitochondrial-flavoprotein homolog that translocates to the nucleus and fragments DNA in a caspase-independent fashion. In parallel, the drug triggers nucleophagy, an autophagic process directed at the cell’s own nucleus. Together, these two processes contribute decisively to the death of the trophozoite, the feeding and pathogenic stage of the amoeba. The finding reframes metronidazole’s lethality as a form of regulated cell death, opening the possibility that drugs designed to modulate these death pathways could potentiate existing therapy.

Transcriptomic studies of resistant Giardia lines add a genome-wide dimension to the resistance story. Analyses of laboratory-selected resistant parasites reveal coordinated changes in genes governing redox metabolism, oxidative stress responses, and energy metabolism. Rather than a single resistance mutation, resistance in Giardia emerges as a systems-level remodeling of cellular physiology: the parasite recalibrates its electron-handling networks to minimize activation of the prodrug, simultaneously bolstering its defenses against the reactive oxygen species that the activated drug generates, and adjusting its energy metabolism to accommodate the loss of pathways it has downregulated. This polygenic architecture helps explain why resistance in the clinic can be variable, difficult to predict, and dependent on the history of drug exposure in a given parasite population.

In Helicobacter pylori, the bacterium responsible for peptic ulcers and gastric cancer, the resistance landscape looks somewhat different. Here, resistance most frequently arises through mutations in, or complete inactivation of, nitroreductase-encoding genes such as rdxA and frxA. Because these enzymes are required to convert metronidazole into its active form, their loss renders the bacterium effectively blind to the drug. Additional mechanisms, including heightened oxidative stress tolerance and cellular efflux systems that pump the compound back out of the cell, can further reduce susceptibility. The contrast between the parasitic and bacterial strategies underscores a common evolutionary theme: pathogens defeat metronidazole either by refusing to activate it or by surviving and expelling its effects once activated, and both routes are being traversed in parallel across the microbial world.

The review frames these diverse findings as evidence of a continuous co-evolutionary contest between metronidazole and the pathogens it targets, a contest in which each side exploits or subverts the other’s biochemistry. The authors argue that decoding these molecular mechanisms is essential for three practical objectives: improving current therapeutic strategies, identifying new drug targets exposed by the activation and death pathways, and designing next-generation nitroimidazole derivatives or combination therapies that circumvent resistance. If activation by the malic enzyme or the NTRs can be pharmacologically enhanced, or if the apoptosis-inducing factor and nucleophagy response can be therapeutically amplified, existing doses might regain potency against resistant strains. Conversely, screening for NIM activity or rdxA mutations could guide precision prescribing. What remains clear is that metronidazole’s future depends on the continued dissection of the very anaerobic biochemistry that made it a miracle drug in the first place, and that this newly consolidated mechanistic framework offers researchers a detailed map for the battles ahead.

Subject of Research: Mechanisms of metronidazole activation, cytotoxicity, and resistance in anaerobic and microaerophilic pathogens

Article Title: Mechanistic insights into metronidazole activation and antiprotozoal action in anaerobic parasites

Article References: Bandyopadhyay, A., & Ghosh, S. K. (2026). Mechanistic insights into metronidazole activation and antiprotozoal action in anaerobic parasites. Frontiers in Parasitology, 5, Article 1946584. https://doi.org/10.3389/fpara.2026.1946584

Image Credits: AI Generated

DOI: 10.3389/fpara.2026.1946584

Keywords: metronidazole, nitroimidazole, Entamoeba histolytica, Giardia lamblia, Trichomonas vaginalis, Helicobacter pylori, PFOR, ferredoxin, nitroreductase, apoptosis-inducing factor, drug resistance, anaerobic parasites